论文部分内容阅读
目的观察孟鲁司特钠联合布地奈德治疗小儿支气管哮喘的临床疗效以及改善肺功能的作用。方法收集60例于2009年10月—2012年3月期间就诊治疗的支气管哮喘患儿,将患儿随机分为两组:对照组30例,治疗组30例,对照组患儿在常规治疗的基础上吸入布地奈德气雾剂(100μg/次,BID,连续使用3个月);治疗组在对照组基础上加用孟鲁司特钠(3～5岁4 mg,6～14岁5mg,口服,QN,连续服用3个月)。结果与对照组比较,治疗组的临床观察指标-治疗前后急性症状发作次数均得到明显改善(P<0.05);肺功能第一秒用力呼气容积(FEV1)、最大呼气流量(PEF)亦有显著改善(P<0.05);对照组的总有效率为70.00%,治疗组为93.34%,二者具有统计学差异(P<0.05)。结论孟鲁司特钠联合布地奈德治疗小儿支气管哮喘的临床疗效显著且能更好的改善肺功能,两者具有协同作用,优于单独使用布地奈德的临床疗效。
Objective To observe the clinical efficacy of montelukast combined with budesonide in the treatment of bronchial asthma in children and to improve the pulmonary function. Methods Sixty children with bronchial asthma were collected from October 2009 to March 2012. The children were randomly divided into two groups: control group (30 cases), treatment group (30 cases), control group On the basis of inhalation of budesonide aerosol (100μg / time, BID, continuous use for 3 months); treatment group on the basis of the control group with montelukast sodium (3 to 5 years old 4 mg, 6 to 14 years old 5 mg , Orally, QN, taking 3 consecutive months). Results Compared with the control group, the clinical observation index - the number of acute symptoms before and after treatment were significantly improved (P <0.05); FEV1 and PEF (P <0.05). The total effective rate was 70.00% in the control group and 93.34% in the treatment group, with statistical significance (P <0.05). Conclusion The combination of montelukast and budesonide has a significant clinical effect in treating children with bronchial asthma and can better improve pulmonary function. Both of them have a synergistic effect and are superior to the clinical efficacy of budesonide alone.